Consortium in €36m series-B for NorthSea Therapeutics

New US-based investors include VenBio and Sofinnova Investments. Existing investors Forbion, Novo Seeds, New Science Ventures (NSV) and BioGeneration Ventures (BGV) also took part in the financing.  

The proceeds of this fundraising will be used by NST to develop ts pipeline of SEFA (structural engineered fatty acids) programmes. The company will develop two additional SEFAs within its clinical pipeline in addition to completing the phase-2b with its lead candidate Icosabutate.

Previous funding
Forbion and BGV previously led a €25m series-A funding round for NST in 2017. Novo Seeds, the corporate venture arm of pharmaceutical company Novo Norsk, and New York-based NSV also took part in the round at the time.

Company
Founded in 2017, NorthSea is a biotechnology company developing strategies for the treatment of NASH (non-alcoholic steatohepatitis) and other metabolic, inflammatory and fibrotic diseases. The company is based in Zierikzee.

People
NST – Rob de Ree (CEO).
Forbion – Sander Slootweg (chairman).
VenBio Partners – Richard Gaster (principal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Benelux
• Healthcare
• Netherlands
• Venture